Executive Team

In addition to his roles as CEO and Chairman of the Board at Receptos, Dr. Rastetter has served since 2006 as Partner at Venrock, a premier venture capital firm. Prior to Receptos and Venrock, Dr. Rastetter was Executive Chairman of Biogen Idec, from the merger of the two companies in 2003 through the end of 2005. He joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion-dollar market valuation company, while serving as Chairman and CEO. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and served as well in a scientific capacity at Genentech. Dr. Rastetter also serves as the Chairman of Illumina, Inc. Adding to his corporate background, Dr. Rastetter held various faculty positions at MIT, won the award for “Excellence in the Teaching of Chemistry” at Harvard and is an Alfred P. Sloan Fellow. He is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering, and biotechnology. Dr. Rastetter holds a B.S. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.

Dr. Boehm brings extensive medicinal chemistry, drug discovery and development expertise in the fields of oncology, inflammation and metabolic diseases. He formerly served as Vice President of Chemistry at Conforma Therapeutics until the successful $250M acquisition by Biogen Idec in 2006. While at Conforma, he directed chemistry efforts resulting in the discovery of CNF1010 and CNF2024 Hsp90 inhibitors in the clinic for oncology indications. Prior to joining Conforma, Dr. Boehm held various positions with progressing responsibility in medicinal chemistry at Ligand Pharmaceuticals. There he successfully led chemistry efforts on multiple intracellular receptor (IRs) programs resulting in the discoveries of Panretin®, Targretin® and LGD1550 retinoids. Dr. Boehm has over 100 patents and publications in the fields of intracellular receptors, Hsp90 and kinase chemistry. He received a B.A. in Chemistry from the University of California, San Diego, a Ph.D. in Chemistry from State University of New York Stony Brook and completed a National Institutes of Health Postdoctoral Fellowship at Columbia University.

Ms. Mineo comes to Receptos with over 20 years experience in the biotechnology industry. In her most recent position, Ms. Mineo was Senior Director of Business Development for Neurocrine Biosciences, where she spent 12 years specializing in both world-wide and regional development and commercialization collaborations for Neurocrine's GPCR directed therapeutic candidates, predominantly in the areas of CNS, endocrinology, and metabolism. She also led technical due diligence and negotiations for several successfully in-licensed candidates in both preclinical and clinical development. Ms. Mineo established multiple technology collaborations for Neurocrine to support the acceleration of drug discovery efforts in the GPCR field, including in the areas of receptor screening, computational chemistry, and GPRC targeted screening libraries. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing, and business development for such companies as Amgen, DNAX Research Institute, Schering Plough, and Baxter Biotech. She began her career in 1987 with Amgen as a member of a cellular biology team investigating the therapeutic role of Neupogen. Ms. Mineo holds a B.S. in zoology from the University of California, Davis and received her M.B.A. from Duke University's Fuqua School of Business.

Dr. Peach comes to Receptos with 19 years of pharmaceutical and biotechnology company experience, successfully discovering and developing drugs in the areas of autoimmunity/inflammation and oncology. In his most recent position, Dr. Peach was Senior Director of Oncology Discovery at Biogen Idec where he had responsibility for several bicoastal research programs, two of which have entered clinical trials. Dr. Peach was also responsible for leading technical due diligence efforts that lead to a 3-compound co-development deal with Protein Design Labs, acquisition of Conforma Therapeutics, and a venture investment in GlobeImmune incluing a subsequent appointment to their Scientific Advisory Board. Prior to joining Biogen Idec, Dr. Peach held several research positions with increasing responsibility at Bristol-Myers Squibb. During that time he played an integral role in the research and development of Orencia®, now registered for the treatment of rheumatoid arthritis. He also led a program that discovered and developed Belatacept, a drug currently in late stage clinical development for the treatment of solid organ transplant rejection. Dr. Peach has authored over 60 peer-reviewed publications and 11 patents. He received his B.S. and M.S. (1st class honors) from the University of Canterbury and a Ph.D. in Biochemistry from the University of Otago, New Zealand.

Mr. Schmidt joins Receptos bringing to bear extensive finance and operations experience. He was formerly Senior Director of Finance and Operations at Conforma Therapeutics until the successful acquisition by Biogen Idec where he assisted in the transition and integration of the companies. Prior to that, Mr. Schmidt served in various financial and operational roles including Chief Financial Officer for Kent SeaTech Corporation, Controller for Medical Imaging Centers of America, Inc and MCA, Inc. / MCA Concerts, Inc., and Manager of Accounting - Retirement Inns of America, Inc. He has managed the finances, human resources, information technology and facilities of companies from start-up to maturity. He started his career with Coopers & Lybrand and received his B.S. in Accounting and Corporate Finance from Drake University in Des Moines, Iowa.